More than a news website
Follow technology on your terms.
Read independent coverage in English and Arabic, add live headlines to your website, or follow the categories that matter to you through RSS.
FDA Approves the First US Plasmid-DNA Immunotherapy
The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis. The plasmid-DNA immunotherapy reduced surgery frequency in a small open-label trial, but confirmatory studies must still verify durable clinical benefit.
Read the storyStart here
Get the context first
Short explainers and chronological timelines that make the news easier to follow, no background required.
Explainers
Browse allHow Plasmid-DNA Immunotherapy Delivers Genetic Instructions
Engineered plasmids carry genes into cells, which briefly produce selected antigens or immune signals that train the immune system without using a replicating pathogen.
ExplainerHow a Malicious Code-Editor Extension Can Persist Outside Its Install Folder
Editor extensions can execute code with a developer's permissions, write SSH keys and startup files, and leave persistence behind even after the extension itself is removed.
ExplainerHow Phage-Based Nanovaccines Display Tumor Antigens
Engineered bacteriophages can carry repeated tumor-antigen fragments on their protein shells while their DNA supplies an immune-stimulating signal, creating a genetically programmable vaccine scaffold.
ExplainerHow Self-Hosting Changes the Security Boundary Around an AI Model
Self-hosting gives organizations control over data, access and customization, but it also transfers responsibility for isolation, authorization, monitoring and incident response from the model provider to the operator.
Timelines
Browse all
The Battery That Electrified Everything: From Lithium Chemistry to Electric Cars
The mRNA Journey: From Fragile Molecule to Programmable Medicine
The Long Road to Humanoid Robots: From Walking Machines to AI Workers
Trending today
The stories NewTqnia readers are spending time with right now.
Explore the landscape
Discover by topic
The NewTqnia signal
The essential tech briefing, without the noise.
A concise weekly read for builders, leaders, and curious minds.
Thank you for subscribing!
You are now part of the NewTqnia Signal.
One concise email each week. Unsubscribe anytime.